Clinical trials: Stereotactic Ablative Radiotherapy
Prostate Cancer
ABlative Radiotherapy (for) Unfavorable Prostate Tumors
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Trial name
- ABRUPT (NCT04831983)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Milano Bicocca
Metastatic Tumors
Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases
This is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).
- Trial name
- NCT02933242
- Testing
- Stereotactic Ablative Body Radiotherapy
- Where
- Canada
- Volunteers
- 399 people
- Sponsor
- British Columbia Cancer Agency
Lung Cancer
Design and Evaluation of a Novel Methodology for SABR for Lung Cancer
Aims: To increase the number of patients that benefit from Stereotactic Ablative Radiotherapy (SABR) for lung cancer using new treatment methods that reduce the amount of non-cancer tissue receiving a high radiation dose without…
- Trial name
- NCT04928755
- Volunteers
- 30 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Lung Cancer
Effect on Patient Reported Outcomes of VATS and SABR (LILAC)
This study will monitor the effect on patients reported outcomes (PROMs) of VATS resection and SABR for NSCLC delivered at the Leeds Cancer Centre The investigator will support with this information the Shared Decision Making…
- Trial name
- LILAC (NCT02882750)
- Testing
- EORTC QLQ-C30 (version 3.0)., PS Q18, Decision Self-Efficacy Scale
- Volunteers
- 244 people
- Sponsor
- University of Leeds
Liver Cancer, Intrahepatic Cholangiocarcinoma
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
- Conditions
- Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
- Trial name
- NCT07223307
- Testing
- MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Stanford University
Hypertrophic Obstructive Cardiomyopathy
SterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy
Hypertrophic obstructive cardiomyopathy (HOCM) is an inherited myocardial disease which leads to the muscle in the wall of the heart growing and thickening to the point that it blocks blood flow exiting the heart with increasing…
- Trial name
- SELECT (NCT04686487)
- Testing
- stereotactic ablative radiotherapy
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Xiangya Hospital of Central South University
Non-small Cell Lung Cancer Stage I
Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer
Stage 1 non-small cell lung cancer (NSCLC) carries up to 30% chance of relapse in 5 years. This a phase 2 study that aims to determine the pathological complete response of the combination of stereotactic ablative radiotherapy…
- Trial name
- NCT04271384
- Testing
- nivolumab
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- Hospital Israelita Albert Einstein
Oligometastatic Renal Cell Carcinoma
SAbR For Oligometastatic Renal Cell Carcinoma
Hypothesis: Stereotactic ablative body radiation (SAbR) prolongs progression-free survival for patients with oligometastatic kidney cancer (RCC) and delays the initiation of systemic therapy.
- Trial name
- NCT02956798
- Testing
- Stereotactic ablative body radiation (SABR)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Clear Cell Renal Cell Carcinoma
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
Nivolumab (brand name Opdivo): IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity; SABR, dose…
- Trial name
- NCT02781506
- Testing
- Nivolumab, SAbR
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Disease
OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites
Currently, the standard of care for patients with diagnosed metastatic cancer is drug therapy (chemotherapy, targeted therapy, or immunotherapy). However, the approach to oligometastatic disease (1-5 metastases) is evolving.
- Trial name
- OLIGO-10 (NCT06856603)
- Testing
- stereotactic radiation therapy in ablative doses to each metastatic site
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Locally Advanced Pancreatic Cancer
Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)
This prospective interventional clinical study evaluates the efficacy and safety of combining systemic chemotherapy followed by ablative stereotactic body radiotherapy (SBRT) as first-line treatment in adult patients with locally…
- Trial name
- NCT07407231
- Testing
- Ablative Stereotactic Body Radiotherapy (SBRT), Standard First-Line Chemotherapy
- Where
- Slovenia
- Volunteers
- 18 people
- Sponsor
- Institute of Oncology Ljubljana
Prostate Cancer
Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer
Since high risk prostate cancer requires higher radiation, this study is being done to determine the maximum tolerated dose of radiation to the prostate and pelvic regions.
- Trial name
- NCT02353819
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Cancer
A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates
Stereotactic ablative body radiotherapy (SABR) can be considered for patients with so-called "oligometastatic" disease. However, since this is a relatively new technique, information on the optimal scheduling is lacking.
- Trial name
- Destroy (NCT03486431)
- Testing
- Stereotactic Ablative Radiotherapy (SABR)
- Where
- Belgium
- Volunteers
- 90 people
- Sponsor
- Cancer Research Antwerp
Non Small Cell Lung Cancer
Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors
The goal of this observational study is to determine if liquid biopsies from patients with stage I non-small cell lung cancer (NSCLC) can add to the diagnosis of a small lung cancer, or can better detect recurrent lung cancer…
- Trial name
- SABR-DETECT (NCT05921474)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Oligometastasis, Lung Cancer
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients…
- Conditions
- Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer
- Trial name
- ID-COMET (NCT06563388)
- Testing
- Stereotactic Ablative Radiotherapy, Best Practice
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Roswell Park Cancer Institute
Non Small Cell Lung Cancer
OPTIMISE Lung SABR
This study is a phase II multi-centre, randomised study independently evaluating five fraction Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) and three fraction IG-SABR for patients with a peripherally located T1-T2…
- Trial name
- NCT07777614
- Testing
- Five fraction Image-guided Stereotactic Ablative Radiotherapy (IG-SABR) treatment, Investigational three fraction image-guided Stereotactic Ablative Radiotherapy (IG-SABR)
- Where
- Ireland
- Volunteers
- 208 people
- Sponsor
- Cancer Trials Ireland
Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
This phase II trial studies how well stereotactic body radiation therapy with or without nivolumab works in treating patients with stage I-IIA non-small cell lung cancer or cancer that has come back.
- Conditions
- Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm, Lung Non-Small Cell Squamous Carcinoma, Minimally Invasive Lung Adenocarcinoma
- Trial name
- NCT03110978
- Testing
- Nivolumab, Stereotactic Body Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Oligometastatic Gastrointestinal Cancer
The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer
This is a single-center, open-label, single-arm phase I clinical study to exploratory observe and evaluate the efficacy and safety of anti-PD-1 antibody (Camrelizumab for Injection) combined with multisite stereotactic ablative…
- Trial name
- NCT04625894
- Testing
- Stereotactic Ablative Radiotherapy (SABR), Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Fudan University
Cholangiocarcinoma
A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma
This is an Open-label, single-arm, multicenter Phase II pilot study to assess the efficacy and safety of BMS-936558 with stereotactic ablative radiation therapy after induction chemotherapy in cholangiocarcinoma.
- Trial name
- NCT04648319
- Testing
- BMS-936558
- Where
- 4 sites in Belgium, Lebanon and 1 more
- Volunteers
- 1 people
- Sponsor
- American University of Beirut Medical Center
Oligometastasis Hepatocellular Carcinoma
Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma
Oligometastasis is a definition that has been described in the past in the 1990s, and in some patients, metastases are not extensive and are limited to a small number of metastases.
- Trial name
- NCT05173610
- Testing
- Radiation: Stereotactic body radiotherapy (SBRT)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University